人肝內膽管癌細胞HuCCT-1

簡要描述：青旗（上海）生物技術發(fā)展有限公司，總部位于上海浦東新區(qū)，依托本地高校資源，逐步發(fā)展成為以生物技術為主的研發(fā)、生產、培訓為一體的綜合化產業(yè)平臺，在標準化細胞庫建立及細胞藥物前端模型方面成果顯著。公司生產經營原代細胞、細胞系、ELISA試劑盒、感受態(tài)細胞和HPLC檢測等科研產品與服務。我們秉承對用戶負責的態(tài)度，以對科研的高度嚴謹，以嚴格的質量控制，為廣大生物醫(yī)學科研用戶提供更優(yōu)質的服務！

更新時間：2021-05-25

廠商性質：生產廠家

瀏覽次數：579

留言詢價聯系我們

詳情介紹

品牌	其他品牌	貨號	BFN60808823
規(guī)格	T25培養(yǎng)瓶x1 1.5ml凍存管x2	供貨周期	現貨
主要用途	僅供科研	應用領域	醫(yī)療衛(wèi)生,生物產業(yè)

細胞名稱	人肝內膽管癌細胞HuCCT-1
貨物編碼	BFN60808823
產品規(guī)格	T25培養(yǎng)瓶x1	1.5ml凍存管x2
細胞數量	1x10^6	1x10^6
保存溫度	37℃	-198℃
運輸方式	常溫保溫運輸	干冰運輸
安全等級	1
用途限制	僅供科研 3類

培養(yǎng)體系	90%DMEM+10%FBS+1%三抗
培養(yǎng)溫度	37℃	二氧化碳濃度	5%
簡介	人肝內膽管癌細胞HuCCT-1取自56歲男性供體。該細胞源于JCRB
注釋	Part of: Cancer Cell Line Encyclopedia (CCLE) project. Part of: COSMIC cell lines project. Part of: TCGA-110-CL cell line panel. Doubling time: ~55 hours (at 10th passage in RPMI + 10% FBS), ~74 hours (at 25th passage in RPMI + 0.2% LA) (PubMed=2544546). Microsatellite instability: Stable (MSS) (Sanger). Omics: Deep exome analysis. Omics: Deep RNAseq analysis. Omics: DNA methylation analysis. Omics: SNP array analysis. Omics: Transcriptome analysis.
基因突變	Heterozygous for KRAS p.Gly12Asp (c.35G>A) (ClinVar=VCV000012582) (CCLE; Cosmic-CLP). *Heterozygous for MSH6 p.Lys1358fs2 (c.4071_4072insGATT) (CCLE; Cosmic-CLP). Homozygous for TP53 p.Arg175His (c.524G>A) (ClinVar=VCV000012374) (CCLE; Cosmic-CLP).**
HLA信息	/
STR信息	Amelogenin X,Y CSF1PO 11,12 D2S1338 17,18 D3S1358 15 D5S818 12,13 D7S820 10,11 D8S1179 10 D13S317 11,13 D16S539 11,12 (Cosmic-CLP; JCRB; RCB; TKG) 9,11,12 (PubMed=25877200) D18S51 13 D19S433 13 D21S11 31 FGA 20,23 Penta D 10 Penta E 15,18 TH01 7,10 TPOX 8 vWA 18
參考文獻	PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747 Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A. An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines. Cancer Res. 79:1263-1273(2019) PubMed=31068700; DOI=10.1038/s41586-019-1186-3 Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature 569:503-508(2019) PubMed=31077409; DOI=10.1002/hep.30704 Sittithumcharee G., Suppramote O., Vaeteewoottacharn K., Sirisuksakun C., Jamnongsong S., Laphanuwat P., Suntiparpluacha M., Matha A., Chusorn P., Buraphat P., Kakanaporn C., Charngkaew K., Silsirivanit A., Korphaisarn K., Limsrichamrern S., Tripatara P., Pairojkul C., Wongkham S., Sampattavanich S., Okada S., Jirawatnotai S. Dependency of cholangiocarcinoma on cyclin D-dependent kinase activity. Hepatology 70:1614-1630(2019) PubMed=31395879; DOI=10.1038/s41467-019-11415-2 Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M., van 't Veer L.J., Butte A.J., Goldstein T., Sirota M. Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types. Nat. Commun. 10:3574-3574(2019)